Scanning irradiation device for mice in vivo with pulsed and continuous proton beams

2011 ◽  
Vol 50 (3) ◽  
pp. 339-344 ◽  
Author(s):  
Christoph Greubel ◽  
Walter Assmann ◽  
Christian Burgdorf ◽  
Günther Dollinger ◽  
Guanghua Du ◽  
...  
Author(s):  
Florian Kroll ◽  
Florian-Emanuel Brack ◽  
Elisabeth Bodenstein ◽  
Kerstin Brüchner ◽  
Leonhard Karsch ◽  
...  

2020 ◽  
Vol 21 (17) ◽  
pp. 6337 ◽  
Author(s):  
Francesco P. Cammarata ◽  
Giusi I. Forte ◽  
Giuseppe Broggi ◽  
Valentina Bravatà ◽  
Luigi Minafra ◽  
...  

Specific breast cancer (BC) subtypes are associated with bad prognoses due to the absence of successful treatment plans. The triple-negative breast cancer (TNBC) subtype, with estrogen (ER), progesterone (PR) and human epidermal growth factor-2 (HER2) negative receptor status, is a clinical challenge for oncologists, because of its aggressiveness and the absence of effective therapies. In addition, proton therapy (PT) represents an effective treatment against both inaccessible area located or conventional radiotherapy (RT)-resistant cancers, becoming a promising therapeutic choice for TNBC. Our study aimed to analyze the in vivo molecular response to PT and its efficacy in a MDA-MB-231 TNBC xenograft model. TNBC xenograft models were irradiated with 2, 6 and 9 Gy of PT. Gene expression profile (GEP) analyses and immunohistochemical assay (IHC) were performed to highlight specific pathways and key molecules involved in cell response to the radiation. GEP analysis revealed in depth the molecular response to PT, showing a considerable immune response, cell cycle and stem cell process regulation. Only the dose of 9 Gy shifted the balance toward pro-death signaling as a dose escalation which can be easily performed using proton beams, which permit targeting tumors while avoiding damage to the surrounding healthy tissue.


2021 ◽  
Author(s):  
Jerimy Polf ◽  
Carlos A. Barajas ◽  
Gerson C. Kroiz ◽  
Stephen W. Peterson ◽  
Paul Maggi ◽  
...  

Abstract We present Compton camera (CC) based PG imaging for proton range verification at clinical dose rates. PG emission from a tissue-equivalent phantom during irradiation with clinical proton beams was measured with a prototype CC. Images were reconstructed of the raw measured data and of data processed with a neural network (NN) trained to identify “true” and “false” PG events. From these images, we determine if PG images produced by the prototype CC could provide clinically useful information about the in vivo range of the proton beams delivered during proton beam radiotherapy. NN processing of the data was found necessary to allow identification of the proton beam path from the PG images. Furthermore, to allow the localization of the end of the proton beam range with a precision of ≤ 3mm with the prototype CC, ~1 x 109 protons would need to be delivered, which is on the order of magnitude delivered for a standard proton radiotherapy treatment field. To obtain higher precision in beam range determination and to allow imaging a single proton pencil beam delivered within the full treatment field, further improvements in PG detection rates by the CC, NN data processing, and image reconstruction algorithms are needed.


Sign in / Sign up

Export Citation Format

Share Document